Vertex Pharmaceuticals Inc logo

VRTX - Vertex Pharmaceuticals Inc Share Price

$235.83 0.3  0.1%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £46.64bn
Enterprise Value £44.01bn
Revenue £2.78bn
Position in Universe 175th / 6410
Bullish
Bearish
Unlock VRTX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VRTX Revenue Unlock VRTX Revenue

Net Income

VRTX Net Income Unlock VRTX Revenue

Normalised EPS

VRTX Normalised EPS Unlock VRTX Revenue

PE Ratio Range

VRTX PE Ratio Range Unlock VRTX Revenue

Dividend Yield Range

VRTX Dividend Yield Range Unlock VRTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VRTX EPS Forecasts Unlock VRTX Revenue
Profile Summary

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 4, 1989
Public Since July 24, 1991
No. of Shareholders: 1,277
No. of Employees: 2,500
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 257,265,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VRTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VRTX
Upcoming Events for VRTX
Similar to VRTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.